Results 71 to 80 of about 1,054 (155)

Real-world study of adverse events associated with gepant use in migraine treatment based on the VigiAccess and U.S. Food and Drug Administration’s adverse event reporting system databases

Frontiers in Pharmacology
BackgroundThis study aimed to investigate the real-world profile of adverse events (AEs) associated with gepant medications in the clinical treatment of migraines by analyzing data collected from the VigiAccess database and the U.S.
Qiaofang Liang, Xiaolin Liao, Hongwen Wu, Yushen Huang, Taolin Liang, Hailong Li, Hailong Li, Hailong Li   +7 more
doaj   +1 more source

Rimegepant - a breakthrough drug for migraine treatment - literature review

Quality in Sport
Migraine is a chronic condition that manifests itself periodically. It is characterized by recurrent, severe, often hemiplegic, throbbing headaches accompanied by autonomic symptoms in the form of nausea, vomiting, hypersensitivity to noise and light.
Katarzyna Kuleta, Julia Głoskowska, Agata Frańczuk, Michalina Grzelka, Aleksandra Makłowicz, Ewelina Kopczyńska, Angelika Szpulak, Patrycja Karkos, Katarzyna Kuśmierczyk, Natalia Dolata   +9 more
openaire   +2 more sources

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source

Safety of Rimegepant in Adults with Migraine and Cardiovascular Risk Factors: Analysis of a Multicenter, Long-Term, Open-Label Study

Pain and Therapy
Introduction Cardiovascular (CV) risk factors can limit treatment options for migraine. Rimegepant is an orally administered small-molecule calcitonin gene-related peptide receptor antagonist that does not induce vasoconstriction.
David True, Kathleen Mullin, Robert Croop   +2 more
doaj   +1 more source

Neuralgia do trigêmeo secundária: relato de caso de espessamento da dura-máter no cavum do trigêmeo por doença relacionada à IgG4.

Headache Medicine
Introdução: A cefaleia por uso excessivo de analgésicos (CAA) é um desafio terapêutico em pacientes com cefaleia crônica. Este relato apresenta um caso em que o rimegepant, um antagonista do receptor CGRP aprovado para enxaqueca episódica, foi eficaz no
Daiana Magali Micucci, Laura Beccaluva, Ana Karina Guevara, Fiorella Martin Bertuzzi , Frederico Anrriquez, Maria Virginia Borras, Daniel Eduardo Doctorovich   +6 more
doaj   +2 more sources

Rimegepant for migraine: acute efficacy beyond the USA

The Lancet Neurology, 2023
openaire   +3 more sources

Rimegepant Sulfate

American Journal of Health-System Pharmacy, 2020
openaire   +1 more source

Safety of Rimegepant in Patients Using Preventive Migraine Medications: A Subgroup Analysis of a Long-Term, Open-Label Study Conducted in the United States

Journal of Pain Research
Gary Berman,1 Alexandra Thiry,2 Robert Croop3 1Clinical Research Institute, Minneapolis, MN, USA; 2Pfizer Inc., New York, NY, USA; 3Biohaven Pharmaceuticals, New Haven, CT, USACorrespondence: Gary Berman, Clinical Research Institute, 825 Nicollet Mall ...
Berman G, Thiry A, Croop R
doaj  

Improvements in Patient-Reported Outcome Measures Through 64 Weeks' Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension. [PDF]

J Pain Res
Lipton RB, Buse DC, Martin VT, Semel D, Cappelleri JC, Thiry A, Abraham L, Fullerton T.   +7 more
europepmc   +1 more source

Current Evidence on the Use of Calcitonin Gene-Related Peptide-Targeting Therapies in Children and Adolescents. [PDF]

Curr Pain Headache Rep
Shin L, Moon R, Gelfand A.
europepmc   +1 more source